Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction
GendAge
GendAge Weight Loss Study: Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction
2 other identifiers
interventional
75
1 country
1
Brief Summary
Obesity increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers, primarily due to elevated abdominal fat storage. With nearly two-thirds of the UK population living with overweight or obesity, there is an urgent necessity for evidence-based public health guidance to promote healthy weight. Calorie deficit can facilitate weight loss and body fat reduction, leading to health benefits, such as improved blood glucose control. Current weight management advice centres on lifestyle modification, incorporating changes to diet and physical activity to support a calorie deficit. However, existing dieting recommendations fail to consider gender or age. This is a surprising oversight, as it is well established that health outcomes vary significantly between men and women across the lifespan. Further, the menopause may have an impact on fat storage linked to changes in sex hormones. Our recent research, involving both mice and humans, has indicated that females are less responsive to weight loss and fat reduction during dieting. This study aims to understand endocrine and metabolic sex-based differences in obesity and calorie restriction, with a particular focus on women's health. We plan to conduct a diet study with 75 participants, encompassing both younger and older men and women, to monitor changes in energy expenditure and body composition using gold-standard techniques, such as doubly-labelled water. Blood and abdominal fat tissue samples will be collected to investigate how sex hormones might elucidate these differences. The aim of the study is to enhance our understanding of diet and women's health to combat obesity and promote healthy ageing.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 3, 2025
CompletedStudy Start
First participant enrolled
July 9, 2025
CompletedFirst Posted
Study publicly available on registry
July 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
July 18, 2025
July 1, 2025
2.4 years
July 3, 2025
July 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Change in body mass expressed as weight in kilograms (kg)
Measured using digital scale
From baseline (day 1) to end of intervention (day 53); additional measurements taken three times a week throughout the intervention duration
Change in energy expenditure expressed in kilocalories per day (kcal/day)
Measured using stable isotope method - doubly labelled water (DLW) - with urine sample collection
From day 11 (start of the calorie-restricted diet) to the end of the intervention (day 52); with additional doses consumed on day 25 and 39
Secondary Outcomes (12)
Change in resting metabolic rate (RMR) expressed in kcal/day
From day 8 (start of the maintenance diet) to end of the intervention (day 53)
Change in bone mineral content in grams (g)
From day 8 (start of the maintenance diet) to end of the intervention (day 53)
Change in total body water (TBW) in litres (l)
From day 11 (start of the calorie-restricted diet) to end of the intervention (day 53)
Change in total body density expressed in litres (l)
From day 8 (start of the maintenance diet) to end of the intervention (day 53)
Change in body fat-mass percentage (%)
From day 8 (start of the maintenance diet) to end of the intervention (day 53)
- +7 more secondary outcomes
Other Outcomes (7)
Change in glycaemic control in response to caloric restriction diet
Every day of the study (days 1-53)
Change in fasting concentration of glucose
From day 8 (start of the maintenance diet) to end of the intervention (day 53)
Change in fasting concentration of ketones
From day 8 (start of the maintenance diet) to end of the intervention (day 53)
- +4 more other outcomes
Study Arms (5)
Young women
EXPERIMENTALAge: 18 to 40 years old
Young men
ACTIVE COMPARATORAge: 18 to 40 years old
Older women (menopause & no-HRT)
EXPERIMENTALAge 55-65 years, in menopause, not taking Hormonal Replacement Therapy (HRT)
Older women (menopause & HRT)
EXPERIMENTALAge 55-65 years, in menopause, who have continuously taken oestrogen HRT for 24 months
Older men
ACTIVE COMPARATORAge 55-65 years
Interventions
3d maintenance diet (MT, fixed macronutrient composition of 15% protein, 30% fat and 55% CHO), fed to energy requirements (1.3 X RMR)
6 week calorie restricted high protein diet (CR, fixed macronutrient composition as 30% protein, 35% fat and 35% CHO) fed to energy requirements \[0.8 X Resting Metabolic Rate (RMR)\], with stepwise reduction of 100kcal/d at week 3 and 5
Eligibility Criteria
You may qualify if:
- Adults (aged over 18years) who are healthy but overweight/obese (BMI 27-45kg/m2) males and females as:
- women (age 40 or less years)
- men (age 40 or less years)
- women (age 55-65 years) in menopause\*; not taking Hormone Replacement Therapy (HRT)
- men (age 55-65 years)
- women (age 55-65 years) in menopause; taking HRT\*\*
You may not qualify if:
- Potential volunteers will be asked to fill in a health questionnaire at the screening visit to assess their suitability for the study. This information will allow us to exclude participants.
- weight loss medication (e.g. GLP agonists), β-blockers, antihistamines, antipsychotics, benzodiazepines, barbiturates, melatonin, Ritalin, modafinil, soporifics, hypnotics, antiepileptic drugs, diabetes medication (e.g. metformin or insulin).
- Females who are planning to be pregnant, are pregnant or are breastfeeding
- Anyone with coeliac disease or gluten intolerance or food allergy
- Anyone with diagnosed T1 or T2 diabetes
- Anyone suffering from a psychiatric disorder or any type of substance abuse
- Anyone following a vegetarian or vegan diet
- Anyone currently following a weight loss programme (that may be affecting lifestyle, physical activity \& diet) or undergone gastric band/reduction surgery; including GLP agonist (e.g. Semaglutide injection, Ozempic®).
- Anyone currently participating in another research study
- Anyone with unsuitable veins for blood sampling
- Anyone who is unable to fluently speak, read and understand English
- Anyone who is unable to comply to an alcohol-free diet for 6 weeks
- Anyone unable to give fully informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Aberdeenlead
- University of Edinburghcollaborator
Study Sites (1)
Rowett Institute, University of Aberdeen
Aberdeen, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alexandra M Johnstone, Professor
Rowett Institute, University of Aberdeen
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 3, 2025
First Posted
July 15, 2025
Study Start
July 9, 2025
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
July 18, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- Data will be shared with the academic community once this has been published in open access journals
- Access Criteria
- Open access from the project's website to IPD that underline the results reported in scientific publications.
The study will be registered with ClinicalTrials.gov as a data repository. Links to IPD that underlie results in publications will be made available at the appropriate time through the project team's website which will contain a summary of the data compiled.